Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for treating cystic fibrosis:
- Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (2024) NICE technology appraisal guidance 988
- Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over (2025) NICE technology appraisal guidance 1085
This page was last updated: